-
Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement…
-
Mabwell Bioscience’s 9MW3811 Receives NMPA Approval for Clinical Trials in Oncology and Fibrosis
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed IL-11 monoclonal antibody (mAb), 9MW3811. The drug is intended for the treatment of various advanced malignant tumors and fibrotic diseases. Therapeutic Potential…
-
Roche’s Rozlytrek on Track for Priority Review for Pediatric NTRK Fusion Tumor Treatment
•
The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib) is likely to receive priority review status for the treatment of children with NTRK fusion positive locally advanced or metastatic solid tumors. This priority review status is justified by the drug’s eligibility for conditional approval.…
-
Zelixir Biotech Secures Over RMB 100 Million in Series A Financing for Synthetic Biology Pipeline
•
Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly secured more than RMB 100 million (USD 14.1 million) in a Series A financing round. The funding was led by Qingdao Qingchi Venture Capital Fund, with additional investments from HM Capital, Hongfeng Investment, and Q…
-
PathoAI Secures Tens of Millions in Angel Financing for AI-Powered Pathology Solutions
•
PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI), has reportedly raised tens of millions of renminbi in an angel financing round. The funding was led by Hangzhou Taikun Equity Investment Fund Partnership, with participation from Deshi Capital. PathoAI’s Focus on AI Products and…
-
Asieris Pharmaceuticals to Present Phase I Results of APL-1202 Combo at ASCO
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the results of a Phase I clinical study at the American Society of Clinical Oncology (ASCO) annual meeting. The study combines Asieris’ APL-1202 with BeiGene Ltd’s (NASDAQ: BGNE, HKG: 6160) programmed death-1 (PD-1) inhibitor tislelizumab as…
-
MicroPort Endovascular MedTech Announces Private Placement to Fund Innovation and Expansion
•
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up to RMB 1.809 billion (USD 260 million) through a private placement of 21,593,444 shares. The funds raised will be allocated to several key areas, including the construction of global headquarters and the advancement of innovation…
-
Antengene’s ATG-022 Earns FDA Orphan Drug Designations for Gastric and Pancreatic Cancers
•
China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody drug conjugate (ADC), ATG-022, targeting Claudin 18.2, has been granted two Orphan Drug Designations (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer. This brings the…
